New research indicates that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end conventional diet and exercise plans.
Research printed in a major health publication points out that while obese individuals often shed a large proportion of their body weight while on the medication, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying such treatments need to be cognizant of the danger of rapid weight regain when the therapy ends," warns lead investigator Dr. Susan Jebb.
That rate of regain suggests a return to pre-treatment mass in about one and a half years.
Analyzing Approaches
The study, which looked at 37 of studies involving thousands of patients, contrasted the effects of GLP-1 agonists with conventional dieting.
Researchers note that people who shed pounds through diet and exercise usually experience a slower weight regain—around 100 grams monthly—after stopping.
Explaining the Fast Regain
Nutrition scientists believe the way of the drugs explains the heightened rebound.
GLP-1 drugs mimic a natural hormone called GLP-1, which helps regulate appetite.
"Artificially providing the hormone concentrations far above than the body's typical production might result in the body to produce less of its endogenous hormone, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication leads to hunger is no longer kept in check, making overeating much more probable."
An Ongoing Issue?
The NHS suggest the jabs for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
Professionals contend that, considering the likelihood of weight regain, the therapy should be considered ongoing.
This perspective is echoed by drug manufacturers, who note that the findings "emphasize the long-term character of excess weight," comparing it to managing diseases like hypertension.
User Experiences
Users who have come off the jabs describe a sudden resurgence of appetite.
"It felt as if something flipping and you're instantly ravenous," said one woman.
This difficulty is compounded if users have not established sustainable lifestyle or habit modifications during therapy.
Significant Adoption
Figures show that millions of adults in the UK have tried these injections in the past year, with desire continuing to grow.
- Use is greater among women compared to males.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the drugs through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a permanent fix and maintained weight loss likely depends on integrated lifestyle support.
